A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt%26apos;s lymphoma (vol 24, pg 3076, 2013)

作者:Evens A M*; Carson K R; Kolesar J; Nabhan C; Helenowski I; Islam N; Jovanovic B; Barr P M; Caimi P F; Gregory S A; Gordon L I
来源:Annals of Oncology, 2014, 25(7): 1449-1449.
DOI:10.1093/annonc/mdu179